Physician profile
Christopher Markeson
NPI 1013611326
$4,532.79
in general payments reported to CMS, 2019-2025
16 companies · $3,566 in 2025
The $3,566 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $23.01 · 2024: $944 · 2025: $3,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,285 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,284.94 |
| Education | $247.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $714.85 | 2024-2025 | Tremfya, Stelara |
| Ucb, INC. | $671.43 | 2023-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $604.42 | 2025 | |
| Leo Pharma INC. | $463.56 | 2024-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $441.42 | 2025 | Dupixent |
| Galderma Laboratories, L.P. | $312.14 | 2024-2025 | Nemluvio |
| Genzyme Corporation | $265.89 | 2025 | |
| Sun Pharmaceutical Industries INC. | $249.58 | 2024-2025 | |
| Lilly USA, LLC | $173.76 | 2025 | Ebglyss |
| Janssen Scientific Affairs, LLC | $118.21 | 2025 | Tremfya |
| Cipher Pharmaceuticals US LLC | $108.38 | 2025 | Spinosad, Natroba |
| Novartis Pharmaceuticals Corporation | $104.25 | 2024 | |
| Johnson & Johnson Health Care Systems INC. | $95.24 | 2025 | Tremfya |
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Pfizer INC. | $92.36 | 2024-2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $22.31 | 2025 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Markeson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.